Skip to Main Content

Paper Details

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Nature
417
2017
A-485, C646, CBP, CREB-binding protein, HATs, HDACs, Histone deacetylase, acetyl coenzyme A, acetyl-CoA, androgen, androgen receptor, androgen receptor-positive prostate cancer, cancer, cancers, castration-resistant prostate cancer, castration-resistant xenograft, haematological malignancies, histone acetyltransferase domains, histone acetyltransferase paralogues, histone acetyltransferases, histone actyltransferase, histone deacetylases, human, lineage, lineage-specific tumours, malignancies, p300, transcriptional activator, tumour, tumours
Author NameAffiliation
Tamar UzielGlobal Pharmaceutical Research and Development
Chunaram Choudharythe Novo Nordisk Foundation Center for Protein Research, University of Copenhagen
Ronen MarmorsteinPerelman School of Medicine, University of Pennsylvania
Philip A ColeJohns Hopkins University
Kenneth D BrombergGlobal Pharmaceutical Research and Development
  • 1 - 5

Datasets

Release 1.2